Equivalent outcomes with primary and retransplantation in African-American deceased-donor renal allograft recipients.

Autor: Gruber SA; Section of Transplant Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, MI, USA. sgruber@dmc.org, Brown KL, El-Amm JM, Singh A, Mehta K, Morawski K, Cincotta E, Nehlsen-Cannarella S, Losanoff JE, West MS, Doshi MD
Jazyk: angličtina
Zdroj: Surgery [Surgery] 2009 Oct; Vol. 146 (4), pp. 646-52; discussion 652-3.
DOI: 10.1016/j.surg.2009.05.020
Abstrakt: Background: Graft survival following renal retransplantation has been inferior to that following primary allografting, particularly in African Americans (AAs) receiving deceased-donor (DD) kidneys.
Methods: Among 166 AA DD renal allograft recipients transplanted from July 2001 through July 2007, we compared the outcomes of 26 (16%) receiving a second graft with those of 140 primary cases. All patients received either thymoglobulin (ATG) or an IL-2 receptor antagonist for induction, and were maintained on either tacrolimus or sirolimus + mycophenolate mofetil +/- prednisone.
Results: When compared with primary transplants, regrafts received kidneys from older donors, were younger, more sensitized, more likely to receive ATG and to be maintained on prednisone, received more doses of ATG, and were less likely diabetic. There was no difference between primary and retransplant groups in overall patient or graft survival; incidence of acute rejection, CMV infection, BK nephropathy, or new-onset diabetes mellitus; and serum creatinine at 1 year.
Conclusion: AA renal allograft recipients can undergo a second DD transplant with intermediate-term outcomes comparable to that of a primary graft, despite the presence of multiple immunologic and non-immunologic high-risk factors, by extending the course of ATG induction and continuing prednisone therapy in the vast majority of cases.
Databáze: MEDLINE
Externí odkaz: